Sobi has announced a definitive agreement to acquire Arthrosi Therapeutics, strengthening its gout franchise with the addition of pozdeutinurad, an investigational once-daily oral URAT1 inhibitor. 

 

The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.

 

“The acquisition of Arthrosi allows us to expand our gout pipeline with a highly differentiated new asset,” said Guido Oelkers, President and CEO of Sobi. 

 

“Pozdeutinurad has the potential to become the therapy of choice for patients who have progressive gout with persistent and unresolved symptoms despite first-line therapy. The product has the potential to materially accelerate our growth until the mid 2030s, and beyond. We welcome all members of the talented Arthrosi team and are looking forward to working closely together to be able to offer this therapy to patients as soon as possible.”

 

Arthrosi’s founder and CEO, Litain Yeh, expressed enthusiasm for the deal: “We are thrilled to join forces with Sobi and look forward to working together to ensure a seamless transition as they advance pozdeutinurad towards pivotal data and potential regulatory filings. We believe that Sobi's global expertise in commercialisation will accelerate our shared mission to deliver pozdeutinurad's potentially transformative benefits for individuals living with gout.”

 

Under the terms of the agreement, Sobi will pay $950 million upfront in cash, with an additional $550 million in potential clinical, regulatory, and sales milestones. The transaction, expected to close in the first half of 2026, is subject to customary closing conditions.

 

Sobi intends to fund the upfront payment primarily through existing and new credit facilities provided by Handelsbanken and Danske Bank. The acquisition is expected to be highly accretive to Sobi’s mid- to long-term growth and margin trajectory.